Ultimovacs has announced that the Phase II LUNGVAC study (NCT05344209) will be switching the immune ...
Vow has announced several positive announcements so far in December across their product offerings.
Atria records EUR 51m impairments in Sweden. High inflation affecting consumer behaviour, the exit o...
Redeye leaves a comment following Initiator Pharma’s announcement earlier today stating that it will...
Analysguiden inleder bevakning av medicinteknikbolaget Prostatype med motiverat värde 3,7-6,1 kr.
Redeye is encouraged to learn that 2cureX has signed IndiTreat® distribution agreements for Switzerl...
Redeye gives a short comment on today’s news of a directed issue in Annexin, where the proceeds will...
Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I ...
Toleranzia går in i slutskedet av de prekliniska studierna för TOL2, mot Myastenia Gravis.
Redeye comments on Mestro's new agreement with Catena and the launch of a new efficient implementati...
CirChem meddelade den 16 december att de ingått ett nytt femårigt ramavtal med Titab Pac för leveran...
BankNordik just upgraded its net profit guidance for 2022 from DKK 140-170m to DKK 160-190m.
Analysguiden inleder bevakning av den svenska spelutvecklaren med en efterlängtad spellansering i pi...
Redeye comments on LIDDS’ announcement of the proposed decision on a rights issue to strengthen the ...
Background on guidance upgrade During the week, Urb-it announced a few last-mile delivery partnershi...
Redeye initiates coverage of Qlife, which aims to bring clinical grade biomarker testing to the home...
Redeye comments on Velvet Cichlid's offer to buy Sleep Cycle in a cash deal.
Ecoclime växer kraftigt i Q3 men resultatet tyngs av tillträdesstädning från den just utbytta lednin...
The final documentation in patent litigation 879 against Apple and Samsung is now public.
This week’s episode of ProView is on Serial Acquirers, where we dive deep into the art of building p...
